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Abstract
Existing knowledge of genetic variants affecting risk of coronary artery disease (CAD) is largely 
based on genome-wide association studies (GWAS) analysis of common SNPs. Leveraging 
phased haplotypes from the 1000 Genomes Project, we report a GWAS meta-analysis of 185 
thousand CAD cases and controls, interrogating 6.7 million common (MAF>0.05) as well as 2.7 
million low frequency (0.005<MAF<0.05) variants. In addition to confirmation of most known 
CAD loci, we identified 10 novel loci, eight additive and two recessive, that contain candidate 
genes that newly implicate biological processes in vessel walls. We observed intra-locus allelic 
heterogeneity but little evidence of low frequency variants with larger effects and no evidence of 
synthetic association. Our analysis provides a comprehensive survey of the fine genetic 
architecture of CAD showing that genetic susceptibility to this common disease is largely 
determined by common SNPs of small effect size.
Coronary artery disease (CAD) is the main cause of death and disability worldwide and 
represents an archetypal common complex disease with both genetic and environmental 
determinants1,2. To date, 48 genomic loci have been found to harbour common SNPs in 
genome-wide significant association with the disease. Previous GWAS of CAD have tested 
the common disease/common variant hypothesis with meta-analyses typically based on 
HapMap imputation training sets or tagging SNP arrays with up to 2.5 million SNPs (85% 
with MAF > 0.05)3,4. The 1000 Genomes Project5 has considerably expanded the coverage 
of human genetic variation especially for lower frequency and insertion/deletion variants 
(indels). We assembled 60,801 cases and 123,504 controls from 48 studies for a GWAS 
meta-analysis of CAD; 34,997 (57.5%) of the cases and 49,512 (40.1%) of the controls had 
been previously included in our Metabochip-based CAD meta-analysis (Supplementary Fig. 
1)3. Imputation was based on the 1000 Genomes phase 1 version 3 training set with 38 
million variants of which over half are low frequency (MAF < 0.005) and one-fifth are 
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common (MAF > 0.05) variants. The majority (77%) of the participants were of European 
ancestry; 13% and 6% were of south (India and Pakistan) and east (China and Korea) Asian 
ancestry with smaller samples of Hispanic and African Americans (Supplementary Table 1). 
Case status was defined by an inclusive CAD diagnosis (e.g. myocardial infarction (MI), 
acute coronary syndrome, chronic stable angina, or coronary stenosis >50%). After selecting 
variants that surpassed allele frequency (MAF > 0.005) and imputation quality control 
criteria in at least 29 (>60%) of the studies, 8.6 million SNPs and 836K (9%) indels were 
included in the meta-analysis (Fig. 1); of these, 2.7 million (29%) were low frequency 
variants (0.005 < MAF < 0.05).
Scanning for additive associations
The results of an additive genetic model meta-analysis are summarized in Manhattan plots 
(Fig. 2 and Supplementary Fig. 2). 2,213 variants (7.6% indels) showed significant 
associations (P < 5 × 10−8) with CAD with a low false discovery rate (FDR q-value < 2.1 × 
10−4). When these 2,213 variants are grouped into loci, eight represent regions not 
previously reported at genome-wide levels of significance (Fig. 2; Table 1). Of 48 
previously reported loci at genome-wide levels of significance, 47 showed nominally 
significant associations (Supplementary Table 2). The exception was rs6903956, the lead 
SNP for the ADTRP–C6orf105 locus detected in Han Chinese6, which previously showed no 
association in the Metabochip meta-analysis of Europeans and South Asians3. Thirty-six 
previously reported loci showed genome-wide significance (Supplementary Table 2). Monte 
Carlo simulations, guided by published effect-sizes, suggest that our study was powered to 
detect 34 of the previously reported loci (95%CI 31 – 41 loci) at genome-wide significance. 
Hence, our findings are fully consistent with the previously identified CAD loci. The 
majority of the loci showing GWAS significance in the present analysis were well imputed 
(82% with imputation quality > 0.9) (Fig. 3a) and had small effect sizes (odds ratio (OR) < 
1.25) (Fig. 3b). An exception was the lead SNP in the novel chromosome 7q36.1 (NOS3) 
locus, rs3918226, which was only moderately well imputed (quality 0.78) but the validity of 
this association is supported by existing genotype data as it was present on the HumanCVD 
BeadChip available for some of the cohorts used in the present analysis and therefore 
directly measured genotypes could be compared with imputed genotypes (Supplementary 
Table 3)7. Three additional lower frequency and moderately well imputed SNPs in LPA and 
APOE (Fig. 3a), which were not previously reported in CAD GWAS3,4, also showed strong 
associations (LPA: rs10455872 P = 5.7 × 10−39, rs3798220 P = 4.7 × 10−9; APOE: rs7412 P 
= 8.2 × 10−11). The LPA SNPs have been previously shown to be strongly associated with 
CAD in candidate gene studies based on experimental genotype data7,8. SNP rs7412 
encodes the epsilon 2 allele of APOE and it has been well documented that ε2 carriers have 
lower cholesterol levels and significant protection from CAD was confirmed in a large meta-
analysis9 and in the Metabochip study (P = 0.0009)3. However, rs7412 is not present on 
most commercially available genome-wide genotyping arrays and cannot be imputed using 
HapMap reference panels, supporting the value of the expanded coverage of the 1000 
Genomes reference panels. Finally, SNP rs11591147, which encodes the low frequency 
(MAF = 0.01) R46L variant in PCSK9 that has been associated with low LDL cholesterol 
levels and cardioprotection10-13, was imperfectly imputed (quality = 0.61). Nonetheless 
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these data provide the strongest evidence to date for a protective effect of this variant for 
CAD (P = 7.5 × 10−6).
Scanning for non-additive associations
Few GWAS of CAD have systematically scanned for associations that include dominance 
effects and few truly recessive loci have been reported14,15. We used a recessive inheritance 
model to search for susceptibility effects conferred by homozygotes for the minor (i.e. less 
frequent) allele. Two novel recessive loci were identified with MAF 0.09 and 0.36 and 
genotypic OR 0.67 and 1.12 (Table 1, Fig. 2); these loci showed very little evidence of 
association under an additive model (Table 1). A supplementary dominant model analysis 
revealed multiple strong associations with variants that all overlapped with loci identified in 
the additive model analysis (Supplementary Table 4).
MI sub-phenotype analysis
Sub-group analysis in cases with a reported history of MI (~ 70% of total number of cases) 
did not identify any additional associations reaching genome-wide significance. The 
association results for the MI sub-phenotype for the 48 previously known CAD loci and the 
8 novel additive CAD loci discovered in this study are shown in Supplementary Table 5. 
Supplementary Fig. 3 compares the OR for the lead SNPs at 56 loci for the broader CAD 
phenotype (full cohort) and the MI sub-phenotype. While, as expected, for most of the loci 
the ORs are very similar, for ABO and HDAC9 the ORs are sufficiently distinct for their 
95% confidence intervals to lie away from the line of equality, suggesting that ABO 
preferentially associates with MI and HDAC9 with stable coronary disease but not infarction 
per se.
FDR and heritability analysis
We performed a joint association analysis to search for evidence of synthetic associations16 
where multiple low-frequency susceptibility variants at a locus might be in LD with a 
common variant that is discovered as the lead variant in a GWAS, and to compile an FDR-
defined list of informative variants for annotation and heritability analysis3. Variants that 
showed suggestive additive associations (P < 5 × 10−5) were assigned to 214 putative 
susceptibility loci centred on a lead variant ±1 centiMorgan and all variants in these loci 
examined; consequently the search space for the joint analysis included 1,399,533 variants. 
Using the GCTA software17 to perform an approximate joint association analysis (Online 
Methods), we identified 202 variants (q-value < 0.05) in 129 loci (Supplementary Table 6) 
with multiple (2 – 14) tightly linked variants in 57% of CAD loci. The 202 FDR variants 
were mostly common (median MAF 0.22) and well imputed (median imputation quality 
0.97). 95 variants (explaining 13.3±0.4% of CAD heritability) mapped to 44 GWAS 
significant loci. 93 variants (explaining 12.9±0.4% of CAD heritability) mapped to loci that 
include a previously reported GWAS significant variant; 109 variants (explaining a further 
9.3±0.3% of CAD heritability) mapped to other loci. Fifteen low frequency (MAF < 0.05) 
variants explained only 2.1±0.2% of CAD heritability noting that our study was ~90% 
powered to detect OR > 1.5 with low frequency variants (Supplementary Table 7).
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Common variants showing typical GWAS signals might be coupled with one or more low 
frequency variants with relatively large effects16. We found no evidence for such synthetic 
associations in the joint association analysis i.e. all low frequency variants were either lead 
variants or jointly associated (q-value < 0.05) with a common variant. Twenty of the 202 
FDR variants (9.9%) were indels (4–14 bp size) compared to 8.8% of all the variants in the 
meta-analysis (P = 0.60). Low frequency variants (MAF < 0.05) were strikingly 
underrepresented (6.9% vs. 29.0%; P = 4.9 × 10−12) which may reflect on the statistical 
power to detect modest effects associated with these variants (vide infra).
Annotation and ENCODE analysis
Functional annotations were assigned to the 9.4 million variants studied in the CAD additive 
meta-analysis using the ANNOVAR software18 (Supplementary Table 8). The 202 FDR 
variants were depleted in intergenic regions (P = 2.5 × 10−7) and enriched in introns (P = 
0.00035). Variants were also assigned to three sets of ENCODE (Encyclopedia of DNA 
Elements) features, namely histone/chromatin modifications (HM), DNase I hypersensitive 
sites (DHS) and transcription factor binding sites (TFBS) (Supplementary Table 9). The 
FDR variants showed independent enrichment across 11 cell types for the HM (P = 2.8 × 
10−6) and DHS (P = 0.0003) ENCODE feature sets and with genic annotation status (P = 
0.0013) (Supplementary Table 10 and Supplementary Table 11). These associations were 
also evident in three cell types selected with maximal CAD relevance with a 2.6-fold 
enrichment for DHS, 2.2-fold enrichment for HM and 1.6-fold enrichment for genic status 
(Supplementary Table 12 and Supplementary Table 13). These findings suggest that the 202 
FDR variants are enriched for functional variants with potential relevance to CAD 
pathogenesis.
Post hoc power calculations
8.2M of 9.4M (87%) of the analysed variants were highly powered (> 90%) to detect an OR 
≥ 1.3 (Supplementary Table 7). The number of variants with power ≥ 90% to detect 
associations varies systematically with allele frequency and imputation quality 
(Supplementary Fig. 4 for OR = 1.3); 1.5M of 2.7M (55%) low frequency variants (0.005 < 
MAF < 0.05) in the meta-analysis were adequately powered to detect an OR ≥ 1.3 as most of 
these variants were accurately imputed (median imputation quality 0.94, interquartile range 
0.88, 0.98). With more common variants (MAF > 0.05) almost all (99.8%) were highly 
powered to detect OR ≥ 1.3. However, in terms of the total coverage of low frequency 
variation, only 15.3% of 9.3M low frequency (0.005 < MAF < 0.05) variants in the 1000 
Genomes phase 1 v3 training set surpassed the allele frequency and imputation quality entry 
criteria in the 60% of the studies required for inclusion in the meta-analysis and were 
predicted to be adequately powered to detect significant associations; 100% of these variants 
were highly powered (>90%) to detect OR ≥ 3.15.
Interrogation of 10 novel additive and recessive loci
We examined whether there were any eQTLs, associations with known cardiovascular risk 
factors or prior evidence of involvement of genes with atherosclerotic processes in each of 
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the newly identified loci to define putative mechanisms by which the loci may affect risk of 
CAD.
Chromosome 4q12 (REST – NOA1) locus: The lead SNP rs17087335 lies within an intron of 
the nitric oxide associated 1 (NOA1) gene; 23 SNPs in linkage disequilibrium (LD r2>0.8) 
show CAD associations (P < 1 × 10−6) across the NOA1 and the repressor element-1 
silencing transcription factor (REST) genes (Fig. 4a). NOA1 is a GTP binding protein 
involved in the regulation of mitochondrial respiration and apoptosis19. REST is a 
transcription factor that suppresses the expression of voltage dependent sodium and 
potassium channels20 and has been shown to maintain vascular smooth muscle cells in a 
quiescent non-proliferative state and is itself down-regulated in neointimal hyperplasia21. 
SNP rs17087335 shows a cis-eQTL signal with REST in lung22 (Supplementary Table 14).
Chromosome 7q36.1 (NOS3) locus: The lead SNP rs3918226 (MAF = 0.07) lies in the first 
intron of the nitric oxide synthase 3 (NOS3) gene (Fig. 4b). This SNP has been tentatively 
associated with CAD (OR = 1.14, P = 1.4 × 10−4) in a candidate gene meta-analysis based 
on 15.6K cases and 35K controls genotyped with the HumanCVD BeadChip7 and firmly 
associated with essential hypertension (OR = 1.34, P = 1.0 × 10−14)23. NOS3 is involved in 
production of nitric oxide (NO), a potent vascular smooth muscle relaxant and a well-
studied candidate gene for CAD. Indeed, proteins forming the NO receptor (soluble 
guanylyl cyclase) display both linkage as well as genome-wide association with CAD3,24. 
There are several overlapping ENCODE features in the NOS3 intron 1 suggesting a 
functional role for rs3918226. However, there are 30 genes neighbouring NOS3 within a ±1 
centiMorgan window and the current data does not allow candidacy of these genes to be 
excluded. A non-synonymous SNP, rs1799983, in NOS3 previously associated with 
cardiovascular phenotypes25 is in weak LD with rs3918226 but did not achieve significance 
in an additive or joint association analysis.
Chromosome 11p15.4 (SWAP70) locus: SNP rs10840293 is intronic to the switch-associated 
protein-70 gene (SWAP70) (Fig. 4c). SWAP-70 is a signalling molecule involved in the 
regulation of filamentous-actin networks26 in cell migration and adhesion. SNP rs10840293 
with other SNPs in strong LD are cis-eQTLs in naïve and challenged monocytes27, SNP 
rs93138 shows a strong association with CAD (P = 5.5 × 10−8) and is a cis-eQTL in naïve 
and challenged monocytes28, fat29, skin29 and lung22 (Supplementary Table 14); three of 
these SNPs (rs93138, rs173396 and rs472109) are intronic and lie within ENCODE 
regulatory functional elements. Although this CAD-associated locus includes 33 genes, the 
eQTL and ENCODE data implicate SWAP70 as a plausible causal gene and suggest putative 
causal SNPs.
Chromosome 15q22.33 (SMAD3) locus: The lead SNP rs56062135 is intronic to SMAD3 
and the CAD association is tightly localized between two recombination hot spots (Fig. 4d). 
Mice lacking Smad3, a major downstream mediator of TGF-β, show enhanced neointimal 
hyperplasia with decreased matrix deposition in response to vascular injury30. SMAD3 had 
been tentatively associated in an earlier CAD GWAS31, although that lead SNP 
(rs17228212) is in linkage equilibrium with rs56062135, showed modest association (P = 
0.009) in the present GWAS and no evidence of joint association (Supplementary Table 6).
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Chromosome 15q26.1 (MFGE8 – ABHD2) locus: The lead intergenic SNP rs8042271 maps 
117kb upstream of milk fat globule-EGF factor 8 (MFGE8) and 57kb upstream from 
abhydrolase domain-containing protein 2 (ABHD2) (Fig. 4e). MFGE8 (lactadherin) has a 
crucial role in VEGF dependent neovascularization32 and is secreted from activated 
macrophages and binds to apoptotic cells, facilitating phagocytic engulfment33. ABHD234 
has been shown to be expressed in human atherosclerotic lesions with higher levels in 
patients with unstable angina. There were no overlapping risk factor QTL, eQTL or 
ENCODE features to guide the nomination of a putative causal gene.
Chromosome 17q23.2 (BCAS3) locus: The lead intronic SNP rs7212798 lies in the breast 
carcinoma amplified sequence 3 (BCAS3) gene (Fig. 4f). Multiple variants in LD with 
rs7212798 map to BCAS3 introns and show strong association with CAD. BCAS3 encodes 
the Rudhira protein that has been shown to activate Cdc42 to affect actin organization and 
control cell polarity and motility in endothelial cells thus contributing to angiogenesis35.
Chromosome 18q21.32 (PMAIP1 – MC4R) locus: The lead intergenic SNP rs663129 lies 
266 kb downstream of the phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1) 
gene and 200kb downstream of the melanocortin 4 receptor (MC4R) gene (Fig. 4g). 
PMAIP1 is a HIF1A-induced proapoptotic gene that mediates hypoxic cell death by the 
generation of reactive oxygen species36. MC4R is a well-studied obesity-related locus and 
the variant (and corresponding proxy variants) that were associated with higher CAD risk 
were also associated with BMI (P = 6×10−42) and obesity-associated risk factors including 
higher triglyceride and lower HDL concentrations and type 2 diabetes37-41. However, we 
found no eQTL data or ENCODE features for the lead or proxy SNPs to further implicate 
MC4R as the causal gene underlying the CAD susceptibility.
Chromosome 22q11.23 (POM121L9P – ADORA2A) locus: The lead SNP rs180803 lies in 
the non-coding RNA POM121 transmembrane nucleoporin-like 9, pseudogene 
(POM121L9P). A ±1 centiMorgan region spans 1.2Mb and includes 21 variants that are 
genome-wide significantly associated with CAD, most of them in LD (r2>0.6) with the lead 
SNP and mapping to intronic regions of the SPECC1L and ADORA2A genes (Fig. 4h).
Chromosome 12q24.23 (KSR2) locus: The lead SNP rs11830157 (MAF=0.36) associates 
with CAD risk in a recessive model (genotypic OR = 1.12) and is intronic to the kinase 
suppressor of ras 2 (KSR2) gene (Fig. 4i) and overlaps with ENCODE functional elements. 
KSR2 interacts with multiple proteins including AMPK and rare loss-of-function coding 
variants in KSR2 are associated with severe obesity, hyperphagia and insulin resistance, a 
phenotype recapitulated in Ksr2 null mice42.
Chromosome 19q13.11 (ZNF507 – LOC400684) locus: The lead SNP rs12976411 
(MAF=0.09) lies in an uncharacterized non-coding RNA (LOC400684) and is 3.4 kb 3’ of 
ZNF507 (Fig. 4j). The minor allele shows a protective CAD effect (genotypic OR = 0.69) in 
the recessive model. ENCODE analysis of this locus suggests that several SNPs including 
rs12981453 and rs71351160, which are in strong LD (r2>0.8) and intronic to ZNF507 
overlap with ENCODE functional elements.
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Discussion
We demonstrate that the ability of GWAS to investigate the genetic architecture of complex 
traits is enhanced by the 1000 Genomes Project. This has allowed us to conclude that low 
frequency variants of larger effect, synthetic associations and insertion/deletion 
polymorphisms are unlikely to explain a significant portion of the missing heritability of 
CAD. Rather, all ten novel CAD associations identified in the present analysis, as well as all 
but one of the previously identified loci, are represented by risk alleles with a frequency of 
greater than 5%. Thus, this comprehensive analysis strongly supports the common disease/
common variant hypothesis43 given that it was powered to detect MAF < 0.05 variants with 
OR > 1.5. Moreover, risk alleles are significantly clustered within or close to genes and 
enriched in regions with functional annotations. Finally, genes implicated by this unbiased 
approach suggest hypotheses that explore the biology of the arterial vessel wall as a critical 
component of CAD pathogenesis.
The success of the GWAS meta-analysis strategy to map common, small-effect 
susceptibility variants for complex diseases has leant heavily on genotype imputation with 
publically available training sets. The 1000 Genomes Project provides a substantial step-up 
from the HapMap era in terms of coverage of lower frequency variants and the integration of 
insertion/deletion polymorphism (Fig. 1). Lead SNPs for 4 of the 10 novel CAD loci were 
either absent or imperfectly tagged (r2 < 0.8) in the HapMap2 training set, which reduced 
the power of discovering these loci in previous GWAS meta-analyses. Although lower 
frequency variants often show geographical differentiation5, the phase1 v3 training set 
includes numerous low MAF variants that are tractable to a global meta-analysis that 
includes multiple continental ancestry groups. Key SNPs in apolipoproteins E and (a) and 
PCSK9, which mediate their CAD-effects via LDL-cholesterol linked mechanisms showed 
strong associations and reinforces the sensitivity of our 1000 Genomes analysis to detect 
lower frequency, imperfectly imputed susceptibility variants which were missed in HapMap-
based GWAS.
Association analysis under the customary additive inheritance model widely used in GWAS 
analyses is optimally powered to detect traits with no dominance variance but conveniently 
has adequate power to detect dominantly inherited traits as well44. However, the additive 
model is systematically underpowered to detect recessively inherited traits particularly for 
lower frequency alleles44. This motivated our recessive meta-analysis, which revealed two 
novel CAD loci, KSR2 and ZNF507-LOC400684 that escaped detection in a conventional 
additive association scan.
Our GWAS explores two potential sources of missing heritability for CAD as it includes 
indels and an extended panel of lower frequency variants. Although there was no evidence 
that indels were systematically enriched for CAD associations, they were present in 10% of 
the 202 variants with an FDR q-value < 5%. In terms of surveying the totality of human 
genetic variation, the 1.5M of 2.7M lower frequency variants that were included in the meta-
analysis with power to detect moderate-penetrance alleles (OR > 1.3) might seem modest. 
Yet the relative paucity of significant associations, 15 variants with MAF < 0.05 that explain 
2% of CAD heritability and provide no evidence of synthetic associations, will temper 
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expectations for the role of low frequency variants underlying CAD susceptibility, 
specifically with respect to risk prediction in a population-based setting. It is though 
important to acknowledge that GWAS based on SNP array data has limited power to resolve 
genes carrying rare mutation burdens. For example, LDLR45, APOA545, APOC346 and 
NPC1L147 are loaded with susceptibility or protective mutations for CAD. These 
discoveries were only revealed by whole-exome sequencing studies in large series of cases 
and controls yet explain less than 1% of the missing heritability of CAD45.
Annotation analysis showed that the CAD associated variants were significantly clustered 
within or close to genes. Furthermore, there was a strong and independent enrichment for an 
overlap of the CAD associations with ENCODE features, particularly in cell types relevant 
to CAD pathogenesis. This phenomenon has been previously reported for other diseases and 
traits48 and can guide candidate gene nomination and the design of future functional studies. 
We found few suggestions of overlap with risk factor QTL or eQTL in available datasets; 
this may in part reflect that the use of proxy variants can be limiting in cross-referencing 
1000 Genomes and HapMap association databases.
Coronary atherosclerosis underlies the development of the vast majority of cases of MI; 
therefore the two are intimately related. However, additional factors such as plaque 
vulnerability or the extent of the thrombotic reaction to plaque disruption may predispose to 
MI in the presence of CAD49. We confirmed that ABO is particularly associated with risk of 
MI50 suggesting that this locus may specifically increase the risk of plaque rupture and/or 
thrombosis. In contrast, HDAC9 showed a stronger association with CAD than with MI 
suggesting that it might predispose to atherosclerosis but not the precipitant events leading 
to an MI. However, HDAC9 shows even stronger associations with ischemic strokes 
involving thrombosis or embolism due to atherosclerosis of a large artery51. Although 
further epidemiological as well as experimental data are required to substantiate these 
findings, they suggest that certain loci may affect distinct mechanisms related to the 
development and progression of CAD.
Several of the genes implicated to date in large-scale analyses of CAD susceptibility encode 
proteins with a known role in the biology of circulating risk factors for CAD, notably lipid 
levels and the metabolism of lipoproteins; others relate to other known atherosclerosis risk 
factors, such as genes implicated in systemic inflammation and in hypertension. This is 
unsurprising, partly because of the undoubted importance of these known risk factors in the 
etiology of CAD but also because some of these prior analyses particularly targeted genes 
involved in risk factor traits, for example the HumanCVD BeadChip52 was based on 
candidate genes and the Metabochip3,53 drew on prior association data with risk factor traits 
as well as an earlier HapMap2 CAD GWAS meta-analysis54. The current experiment adopts 
a completely unbiased approach and is the first to do so at very large scale. In this respect, it 
is notable that for some of the novel loci where genomic data, biological precedent and 
eQTL associations suggest a plausible novel CAD gene, the genes so implicated have well 
documented roles in vessel wall biology. Their gene products are involved in diverse 
processes including cell adhesion and leukocyte and vascular smooth muscle cell (VSMC) 
migration (SWAP7026 and ABHD255), VSMC phenotypic switching (REST20), TGF-β 
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signaling (SMAD356,57), anti-inflammatory and infarct sparing effects (ADORA2A58 and 
MFGE859), angiogenesis (BCAS335) and nitrous oxide signaling (NOS324).
It is important to note that these putative new susceptibility genes require substantial further 
investigation and validation before firm vascular biology links can be established. A number 
of preventative strategies target the vessel wall (control of blood pressure, smoking 
cessation) but the large majority of existing drug treatments for lowering CAD risk operate 
through manipulating circulating lipids and few directly target vessel wall processes. 
Detailed investigation of new aspects of vessel wall biology that are implicated by genetic 
association, but have not previously been explored in atherosclerosis, may provide new 
insights into its complex aetiology and hence new targets.
Online Methods
Association Analysis
Three models of heritable disease susceptibility were analysed by logistic regression 1) an 
additive model where the log(genotype risk ratio) (log(GRR)) for a genotype was 
proportional to the number of risk alleles, 2) a recessive model where the log(GRR) for 
homozygotes for the minor allele was compared with a reference risk in pooled 
heterozygotes and homozygotes for the major allele and 3) a dominant model where the 
log(GRR) for homozygotes for the minor allele pooled with heterozygotes was compared 
with a reference risk in homozygotes for the major allele. Minor and major alleles were 
identified by reference to the allele frequencies in the pooled populations (i.e. all continents) 
of 1000 Genomes phase 1 v3 data. For the recessive and dominant analyses, genotype 
probabilities to allow for variable imputation quality were analysed by all contributing 
studies; for the additive analysis, genotype probabilities or allelic dosages were used 
(Supplementary Table 1).
Data Quality Control
Association data for each contributing study were individually filtered by MAF > 0.005 
(estimated in combined cases and controls) and an imputation quality metric, rsq > 0.3 for 
minimac or info_proper > 0.4 for IMPUTE261. Allele frequencies for each study were 
binned and compared with other studies to detect systematic flipping of alleles 
(Supplementary Fig. 5). Over-dispersion of association statistics was assessed by the 
genomic control method62 (Supplementary Table 15) and adjusted values were submitted 
for meta-analysis. Variants that were retained in at least 60% of the studies were submitted 
for meta-analysis using the GWAMA program63. Following an inverse-variance weighted 
fixed-effects meta-analysis, heterogeneity was assessed by Cochran’s Q statistic64 and the I2 
inconsistency index65 and variants showing marked heterogeneity were reanalysed using a 
random-effects model66. Over-dispersion in the resulting meta-analysis statistics was 
adjusted for by a second application of the genomic control procedure (Supplementary Fig. 
6).
Nikpay et al. Page 9
Nat Genet. Author manuscript; available in PMC 2016 April 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
FDR estimation
The false discovery rate (FDR) was assessed using a step-up procedure encoded in the 
qqvalue Stata program67. This procedure has been reported to be well controlled under 
positive regression-dependency conditions68; simulations based on 1000 permuted replicates 
of the PROCARDIS imputed data demonstrated that the FDR was conservatively controlled 
(theoretical q-value = 0.05, empirical q-value = 0.026 95%CI 0.017 – 0.038) in the context 
of the linkage disequilibrium patterns prevalent in the 1000 Genomes phase 1 v3 training 
set.
GCTA and heritability analysis
Joint association analysis of the CAD additive meta-analysis results was performed using 
the GCTA software17 that fits an approximate multiple regression model based on summary 
association statistics and linkage disequilibrium information derived from a reference 
genotype database (here the 1000 Genomes phase 1 v3 training set for all continents/
populations that includes genotypes for 1,092 individuals). In this analysis, the lead variant 
is not necessarily retained in the final joint association model in situations where there might 
be multiple associated variants in strong LD. The accuracy of this analysis depends on 
appropriate ancestry matching as well as the sample size of the reference genotype panel to 
ensure that estimated LD correlations are unbiased and acceptably precise69. Simulations 
suggest that the expected correlation between p-values based on the GCTA method using a 
reference panel of 1,000 genotyped samples and p-values from an “exact” multiple 
regression based on experimental genotypes will be between 0.90 and 0.9569. We 
investigated the empirical accuracy of the GCTA joint association analysis by comparing 
GCTA joint association results with a standard multiple logistic regression analysis in 4 
contributing studies (Supplementary Fig. 7). This showed that 95% of the betas and SE were 
accurately approximated. The −log10 p-values from the two analyses were positively 
correlated (0.86 < rho < 0.93) with the GCTA method showing an insignificant trend (P > 
0.20) to yield slightly inflated values.
Heritability calculations were based on a multifactorial liability threshold model70 assuming 
that the disease prevalence was 5% and that the total heritability of CAD was 40%3; 
multiple regression estimates of allelic effect sizes were used following the GCTA joint 
association analysis. Standard errors of the heritability estimates were estimated by Monte 
Carlo sampling with 1,000 replicates (i.e. for each variant, draw effect sizes (beta) randomly 
from the variants’ beta±SE estimate, calculate heritability for each beta-by-replicate draw, 
sum heritability across N variants within each replicate and finally calculate the standard 
error of the heritability estimates across the 1,000 replicates).
Power Calculations
The power to detect genetic associations depends on the magnitude of the genetic risk (i.e. 
effect size), the type 1 error rate, the risk allele frequency and imputation quality and the 
sample size. Non-centrality parameter calculations were based on double genomic controlled 
standard error estimates from the additive model meta-analysis; these estimates integrate 
information on allele frequency, imputation quality and sample size, which typically vary 
across studies. The type 1 error was set at 5 × 10−8 and an additive risk model was assumed.
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Risk Factor QTL survey
The 10 novel CAD associated loci were scanned for associations with CAD heritable risk 
factors using publically available resources including large-scale GWAS consortia data 
downloads37-41,71-73 and the NHGRI GWAS catalogue accessed May 201474. As previous 
risk factor GWAS were mainly based on HapMap2 imputed datasets, all SNPs in LD (r2>0.8 
based on 1000 Genomes phase 1 v3 ALL reference panel) with the novel variants were 
examined for risk factor associations. The novel associated loci were cross-referenced with 
known cis and trans eQTL associations from the University of Chicago eQTL browser 
(accessed July 2014), the GTEx Portal (accessed June 2014), the Geuvadis Data Browser 
(accessed June 2014) and other published data22,28,29,75-79.
Annotation and ENCODE analysis
Variants were annotated using the ANNOVAR18 (version Aug 2013) software based on a 
GRCh/hg19 gene annotation database. Upstream/downstream status was assigned to variants 
that mapped ≤1kb from the transcript start/end. Variants without intergenic annotation were 
assigned a genic annotation status (42%). Supplementary Table 8 shows the annotation 
status of 9.4M variants included in the CAD additive meta-analysis; 86% of the genic 
variants map to introns.
ENCODE features were downloaded from the Ensembl database using the Funcgen Perl 
API module release 75. The list of the ENCODE experiments stored in the Ensembl 
database can be browsed at http://Feb2014.archive.ensembl.org/Homo_sapiens/Experiment/
Sources?db=core;ex=project-ENCODE-. This summarized 100 different types of functional 
evidence in 11 different cell types, a total of 379 ENCODE experiments that revealed 
6,099,034 features. Variants that overlaid one or more of these features were cross-tabulated 
with their ANNOVAR annotation status (Supplementary Table 10); 50% of variants mapped 
to one or more ENCODE features and variants in ENCODE features were strongly enriched 
for genic annotation status. Variants were grouped into three functional sets, histone/
chromatin modifications (HM), DNase I hypersensitive sites (DHS) and transcription factor 
binding sites (TFBS) (Supplementary Table 9). Cell types were grouped into CAD relevant 
and others (Supplementary Table 12) based on their potential roles in CAD 
pathophysiology; hepatocytes (e.g. lipid metabolism80), vascular endothelial cells 
(atherosclerosis81) and myoblasts (injury/repair82) were selected as being most relevant to 
the CAD phenotype. Multi-way contingency tables reporting ENCODE feature and 
ANNOVAR annotation status with inclusion in the FDR < 5% variant list (FDR202 status) 
are summarized for 11 ENCODE cell types in Supplementary Table 11 and for the three 
CAD relevant cell types in Supplementary Table 13. Contingency table counts were 
modelled by a logistic multiple regression model predicting FDR202 status with 
independent explanatory variables HM, DHS, TFBS and genic/intergenic status. The 
ENCODE83 project has previously mapped 4,492 GWAS significant SNPs from the NHGRI 
(June 2011) catalogue74 to TF (12%) and DHS (34%) features in an extended dataset of 
1,640 experiments. The 202 FDR variants were slightly less prevalent in these feature 
groups (10.4% TF and 19.8% DHS) which could reflect a CAD-specific issue or a more 
general consequence of our analysis being based on a subset of the ENCODE data retrieved 
from the Ensembl database.
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Figure 1. 
Spectrum of minor allele frequencies (MAF) and median imputation quality (MEDIAN 
INFO) showing the number (N) of variants in each bin (a) shows the distribution for the 
9.4M 1000 Genomes phase1v3 variants (b) shows the distribution for 2.5M HapMap2 SNPs. 
Imputation quality was calculated as the median of the respective values in up to 48 
contributing studies; the imputation quality for genotyped variants was set equal to 1.0. The 
1000 Genomes training set included more low frequency variants, many of which have 
imputation qualities > 0.9.
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Figure 2. 
A circular Manhattan plot summarizing the 1000 Genomes CAD association results. The 
meta-analysis statistics have been adjusted for over-dispersion (before double genomic 
control, lambda = 1.18); over-dispersion is predicted to be a regular feature in GWAS under 
the polygenic inheritance model60. The association statistics have been capped to P = 1 × 
10−20. Genome-wide significant variants (P < 5 × 10−8) are indicated by red triangles. Novel 
CAD loci are named in red (Table 1). Previously reported loci showing genome-wide 
significance are shown in black and those showing nominal significance (P < 0.05) in our 
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meta-analysis in blue (Supplementary Table 2). The inner track (see inset) shows the 
imputation quality score of the lead variants of the novel loci. The middle track shows 
numbered chromosome ideograms with the centromeres indicated by pink bars.
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Figure 3. 
Imputation quality and effect size of lead variants at 46 genome-wide significant loci. (a) 
Imputation quality and minor allele frequency (MAF) for lead variants at 46 genome-wide 
significant susceptibility loci. Blue circles indicate novel additive loci, red squares - novel 
recessive loci, black triangles - previously mapped additive loci, black diamonds - key SNPs 
in LPA and APOE. Imputation quality and MAF were calculated as the median of the 
respective values in up to 48 contributing studies; the imputation quality for studies with 
genotype data was fixed at 1.0. (b) Odds ratios and effect allele frequency (EAF) for lead 
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variants at 46 genome-wide significant loci. Blue circles indicate novel additive loci; red 
squares - novel recessive loci, black triangles - previously mapped additive loci. SNPs 
rs55730499 and rs2891168 are lead variants in the LPA and chromosome 9p21 susceptibility 
loci. EAF was calculated as the median value in up to 48 contributing studies.
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Figure 4. 
Regional association plots of the eight additive (a–h) and two recessive (i–j) novel CAD 
loci. The association statistics have been adjusted for over-dispersion following meta-
analysis (genomic control parameter 1.18 for the additive and 1.05 for the recessive models). 
Linkage disequilibrium (r2) calculations were based on the combined 1000 Genomes phase 
1 v3 training dataset. Genomic coordinates in mega-base pairs (Mb) refer to the hg19 
sequence assembly.
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